IIIV vs TYRA vs KROS vs PCOR

For growth investors, Keros Therapeutics, Inc.

(KROS) is the stronger pick with 67. 7% revenue growth year-over-year, versus -7. 3% for i3 Verticals, Inc. (IIIV). Keros Therapeutics, Inc. (KROS) offers the better valuation at 5. 1x trailing P/E, making it the more compelling value choice. Analysts rate i3 Verticals, Inc. (IIIV) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Keros Therapeutics, Inc.

(KROS) is the cheapest at 5. 1x versus i3 Verticals, Inc. at 40. 9x. On forward P/E, i3 Verticals, Inc. is actually cheaper at 20. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Tyra Biosciences, Inc.

(TYRA) delivered a total return of +26. 5%, compared to -78. 1% for Keros Therapeutics, Inc. (KROS). Over 10 years, the gap is even starker: TYRA returned +26. 5% versus KROS's -42. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Tyra Biosciences, Inc.

(TYRA) is the lower-risk stock at 0. 75β versus Procore Technologies, Inc. 's 1. 40β — meaning PCOR is approximately 86% more volatile than TYRA relative to the S&P 500. On balance sheet safety, i3 Verticals, Inc. (IIIV) carries a lower debt/equity ratio of 1% versus 9% for Procore Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Keros Therapeutics, Inc.

(KROS) is pulling ahead at 67. 7% versus -7. 3% for i3 Verticals, Inc. (IIIV). On earnings-per-share growth, the picture is similar: Keros Therapeutics, Inc. grew EPS 146. 0% year-over-year, compared to -87. 9% for i3 Verticals, Inc.. Over a 3-year CAGR, PCOR leads at 22. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Keros Therapeutics, Inc.

(KROS) is the more profitable company, earning 35. 7% net margin versus -7. 6% for Procore Technologies, Inc. — meaning it keeps 35. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KROS leads at 28. 9% versus -8. 9% for PCOR. At the gross margin level — before operating expenses — KROS leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, i3 Verticals, Inc.

(IIIV) trades at 20. 3x forward P/E versus 29. 6x for Procore Technologies, Inc. — 9. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KROS: 781. 4% to $102. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Tyra Biosciences, Inc.

(TYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75)). Both have compounded well over 10 years (TYRA: +26. 5%, PCOR: -39. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IIIV (Technology) and TYRA (Healthcare) and KROS (Healthcare) and PCOR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IIIV is a small-cap quality compounder stock; TYRA is a small-cap quality compounder stock; KROS is a small-cap high-growth stock; PCOR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.